The US Food and Drug Administration approved Foundation Medicine’s FoundationOne Liquid CDx companion diagnostic to aid in identifying patients who may respond to treatment with Novartis’ Tabrecta (capmatinib), the company announced 15 July.
The FDA approved Tabrecta in 2020 as the first therapy approved for targeting metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14)....